Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ASTHMA
MCID: AST005
MIFTS: 77

Asthma (ASTHMA)

Categories: Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Asthma

About this section

MalaCards integrated aliases for Asthma:

Name: Asthma 56 12 74 52 73 73 36 29 54 6 42 3 43 15 37 62 62 17 71 32
Chronic Obstructive Asthma 12 54 17 71
Asthma, Susceptibility to 56 29 6 39
Asthma, Diminished Response to Antileukotriene Treatment in 56 13 6
Bronchial Hyperreactivity 12 54 71
Asthma, Nocturnal, Susceptibility to 56 6
Asthma, Protection Against 56 6
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma-Related Traits, Susceptibility to 56
Asthma, Exercise-Induced 71
Exercise Induced Asthma 12
Exercise-Induced Asthma 12
Asthma Exercise-Induced 54
Asthma-Related Traits 56
Asthma, Bronchial 56
Asthma, Nocturnal 56
Bronchial Asthma 73

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant vs. multifactorial


HPO:

31
asthma:
Inheritance autosomal dominant inheritance multifactorial inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Respiratory diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2841
OMIM 56 600807
KEGG 36 H00079
ICD9CM 34 493 493.9
MeSH 43 D001249
NCIt 49 C28397
SNOMED-CT 67 21341004
SNOMED-CT via HPO 68 195967001 263681008 991000119106
UMLS 71 C0004096 C0004099 C0085129 more
Sources

Summaries for Asthma

About this section
MedlinePlus : 42 Asthma is a chronic disease that affects your airways. Your airways are tubes that carry air in and out of your lungs. If you have asthma, the inside walls of your airways become sore and swollen. That makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. When your airways react, they get narrower and your lungs get less air. Symptoms of asthma include Wheezing Coughing, especially early in the morning or at night Chest tightness Shortness of breath Not all people who have asthma have these symptoms. Having these symptoms doesn't always mean that you have asthma. Your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. You may also have allergy tests. When your asthma symptoms become worse than usual, it's called an asthma attack. Severe asthma attacks may require emergency care, and they can be fatal. Asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Asthma, also known as chronic obstructive asthma, is related to allergic asthma and intrinsic asthma, and has symptoms including coughing, recurring periods of wheezing and chest tightness. An important gene associated with Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Asthma and Allograft rejection. The drugs Nebivolol and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include Lung, testes and t cells, and related phenotype is asthma.

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases : 52 Asthma is a breathing disorder that affects the airways. People with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. Most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. Asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic , environmental, and lifestyle factors. Many people with asthma have a personal or family history of allergies, such as hay fever or eczema. Having a family member with asthma is associated with an increased risk of developing the condition. Treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack.

OMIM : 56 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

KEGG : 36 Asthma is a complex syndrome with many clinical phenotypes in both adults and children. Its major characteristics include a variable degree of airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Inhaled allergens encounter antigen presenting cells (APC) that line the airway. Upon recognition of the antigen and activation by APC, naive T cells differentiate into TH2 cells. Activated TH2 stimulate the formation of IgE by B cells. IgE molecules bind to IgE receptors located on mast cells. The crosslinking of mast-cell-bound IgE by allergens leads to the release of biologically active mediators (histamine, leukotrienes) by means of degranulation and, so, to the immediate symptoms of allergy. Mast cells also release chemotactic factors that contribute to the recruitment of inflammatory cells, particularly eosinophils, whose proliferation and differentiation from bone marrow progenitors is promoted by IL-5. The activation of eosinophils leads to release of toxic granules and oxygen free radicals that lead to tissue damage and promote the development of chronic inflammation.

Novus Biologicals : 55 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 73 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

PubMed Health : 62 About asthma: Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The coughing often occurs at night or early in the morning. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma. About 7 million of these people are children.

Wikipedia : 74 Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by... more...

Sources

Related Diseases for Asthma

About this section

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1343)
# Related Disease Score Top Affiliating Genes
1 allergic asthma 36.2 RNASE3 NPSR1 IL13 CCL11 ALOX5
2 intrinsic asthma 35.5 RNASE3 IL13 CCL11
3 status asthmaticus 34.8 RNASE3 CCL11 ADRB2
4 ige responsiveness, atopic 34.7 RNASE3 PLA2G7 IL13
5 dermatitis, atopic 34.6 TNF RNASE3 IL13 HLA-G CYSLTR1 CCL11
6 dermatitis 34.4 TNF RNASE3 NPSR1 IL13 CCL11 ALOX5
7 allergic rhinitis 34.4 RNASE3 IL13 CCL11 ALOX5
8 churg-strauss syndrome 34.2 TNF RNASE3 CYSLTR1 CCL11
9 pollen allergy 33.9 RNASE3 IL13 ADRB2
10 rhinitis 33.8 TNF RNASE3 IL13 CYSLTR1 CCL11
11 lung disease 33.7 TNF RNASE3 IL13 ADRB2
12 latex allergy 33.6 TNF RNASE3 IL13
13 esophagitis, eosinophilic, 1 33.6 RNASE3 IL13 CCL11
14 hypereosinophilic syndrome 33.4 RNASE3 IL13 CCL11 ALOX5
15 bronchitis 33.3 TNF RNASE3 IL13 CCL11
16 allergic hypersensitivity disease 33.2 TNF RNASE3 IL13 CYSLTR1 CCL11 ALOX5
17 proteasome-associated autoinflammatory syndrome 1 33.1 TNF RNASE3 IL13 CCL11 ALOX5
18 respiratory failure 33.0 TNF RNASE3 IL13 CCL11 ALOX5 ADRB2
19 urticaria 32.9 TNF RNASE3 IL13 HNMT ALOX5
20 pulmonary disease, chronic obstructive 32.9 TNF RNASE3 MIR126 IL13 CCL11 ADRB2
21 bronchiolitis 32.9 TNF RNASE3 IL13 CCL11
22 conjunctivitis 32.7 TNF RNASE3 IL13 CCL11
23 respiratory allergy 32.6 TNF RNASE3 IL13 CCL11
24 food allergy 32.6 TNF RNASE3 IL13
25 common cold 32.6 TNF RNASE3 IL13 CYSLTR1 CCL11
26 pulmonary eosinophilia 32.4 RNASE3 IL13 CYSLTR1 CCL11
27 eosinophilic pneumonia 32.3 RNASE3 IL13 CCL11
28 body mass index quantitative trait locus 11 32.3 TNF PLA2G7 MIR126 CCL11 BRCA2 ALOX5
29 allergic conjunctivitis 32.2 TNF RNASE3 IL13 CCL11
30 esophagitis 32.1 TNF IL13 CCL11
31 otitis media 32.0 TNF RNASE3 CCL11
32 bronchial disease 31.9 TNF RNASE3 MIR126 IL13 CYSLTR1 CCL11
33 inflammatory bowel disease 31.9 TNF NPSR1 IL13 HLA-G CCL11 ALOX5
34 milk allergy 31.7 TNF RNASE3 IL13
35 gastroenteritis 31.7 TNF RNASE3 CCL11
36 schistosomiasis 31.6 TNF RNASE3 IL13
37 parasitic helminthiasis infectious disease 31.6 TNF RNASE3 IL13 CCL11
38 keratoconjunctivitis 31.5 TNF RNASE3 IL13 CCL11
39 human immunodeficiency virus type 1 31.4 TNF HLA-G CCL11 ALOX5
40 myocardial infarction 31.4 TNF PLA2G7 MIR126 CCL11 ALOX5 ADRB2
41 nose disease 31.3 TNF RNASE3 IL13 CYSLTR1 CCL11
42 skin disease 31.3 TNF RNASE3 MIR126 IL13 CCL11
43 paranasal sinus disease 31.3 TNF IL13 ALOX5
44 vernal keratoconjunctivitis 31.3 RNASE3 IL13 CCL11
45 chronic conjunctivitis 31.0 TNF RNASE3 IL13 CCL11
46 conjunctival disease 31.0 TNF RNASE3 IL13 CCL11
47 diabetes mellitus, insulin-dependent 30.8 TNF PVT1 IL13 CCL11 ADRB2
48 onchocerciasis 30.8 RNASE3 IL13 CCL11
49 cardiovascular system disease 30.6 TNF PLA2G7 MIR126 ALOX5 ADRB2
50 upper respiratory tract disease 30.5 TNF RNASE3 MIR148A IL13 CYSLTR1 CCL11

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Osteoporosis
Respiratory Failure Status Asthmaticus

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma
Sources

Symptoms & Phenotypes for Asthma

About this section

Human phenotypes related to Asthma:

31
# Description HPO Frequency HPO Source Accession
1 asthma 31 HP:0002099

Symptoms via clinical synopsis from OMIM:

56
Resp:
asthma
airway hyperresponsiveness

Clinical features from OMIM:

600807

Symptoms:

12
  • • coughing
  • • recurring periods of wheezing
  • • chest tightness
  • • shortness of breath
  • • mucus production

UMLS symptoms related to Asthma:


dyspnea, cyanosis, wheezing, snoring, coughing, labored breathing, sneezing, spasm, expiratory wheeze
Sources

Drugs & Therapeutics for Asthma

About this section

PubMed Health treatment related to Asthma: 62

Asthma is a long-term disease that has no cure. The goal of asthma treatment is to control the disease. Good asthma control will: Prevent chronic and troublesome symptoms, such as coughing and shortness of breath Reduce your need for quick-relief medicines (see below) Help you maintain good lung function Let you maintain your normal activity level and sleep through the night Prevent asthma attacks that could result in an emergency room visit or hospital stay To control asthma , partner with your doctor to manage your asthma or your child's asthma. Children aged 10 or older—and younger children who are able—should take an active role in their asthma care. Taking an active role to control your asthma involves: Working with your doctor to treat other conditions that can interfere with asthma management. Avoiding things that worsen your asthma (asthma triggers). However, one trigger you should not avoid is physical activity. Physical activity is an important part of a healthy lifestyle. Talk with your doctor about medicines that can help you stay active. Working with your doctor and other health care providers to create and follow an asthma action plan. An asthma action plan gives guidance on taking your medicines properly, avoiding asthma triggers (except physical activity), tracking your level of asthma control, responding to worsening symptoms, and seeking emergency care when needed. Asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines help reduce airway inflammation and prevent asthma symptoms . Quick-relief, or "rescue," medicines relieve asthma symptoms that may flare up. Your initial treatment will depend on the severity of your asthma . Followup asthma treatment will depend on how well your asthma action plan is controlling your symptoms and preventing asthma attacks. Your level of asthma control can vary over time and with changes in your home, school, or work environments. These changes can alter how often you're exposed to the factors that can worsen your asthma. Your doctor may need to increase your medicine if your asthma doesn't stay under control. On the other hand , if your asthma is well controlled for several months, your doctor may decrease your medicine. These adjustments to your medicine will help you maintain the best control possible with the least amount of medicine necessary. Asthma treatment for certain groups of people—such as children, pregnant women, or those for whom exercise brings on asthma symptoms —will be adjusted to meet their special needs.

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 743)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
5
Pancrelipase Approved, Investigational Phase 4 53608-75-6
6
Cisatracurium Approved Phase 4 96946-41-7
7
Etomidate Approved Phase 4 33125-97-2 36339 667484
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
10
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
11
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
12
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
13
Oxcarbazepine Approved Phase 4 28721-07-5 34312
14
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
15
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
16
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
17
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Norflurane Approved, Experimental Phase 4 811-97-2
20
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
21
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
22
Levocetirizine Approved Phase 4 130018-77-8 1549000
23
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
24
Atenolol Approved Phase 4 29122-68-7 2249
25
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
26
Opium Approved, Illicit Phase 4 8008-60-4
27
Belladonna Approved, Experimental Phase 4
28
Loperamide Approved Phase 4 53179-11-6 3955
29 Tomato Approved Phase 4
30
Ticagrelor Approved Phase 4 274693-27-5 9871419
31
Nicotine Approved Phase 4 54-11-5 942 89594
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
33
Ibuprofen Approved Phase 4 15687-27-1 3672
34
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
35
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
36
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
37
Promethazine Approved, Investigational Phase 4 60-87-7 4927
38 Ancrod Approved, Investigational Phase 4 9046-56-4
39
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
40
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
41
Doxazosin Approved Phase 4 74191-85-8 3157
42
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
43 sodium fluoride Approved Phase 4 7681-49-4
44
Triflusal Approved, Investigational Phase 4 322-79-2
45
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
46
Hydroxyzine Approved Phase 4 68-88-2 3658
47
Prazosin Approved Phase 4 19216-56-9 4893
48
Codeine Approved, Illicit Phase 4 76-57-3 5284371
49
Chlorpheniramine Approved Phase 4 113-92-8, 132-22-9 2725
50
Cetirizine Approved Phase 4 83881-51-0 2678

Interventional clinical trials:

(show top 50) (show all 4656)
# Name Status NCT ID Phase Drugs
1 Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
2 Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
3 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
4 Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Unknown status NCT02934945 Phase 4 budesonide 160μg/formoterol 4.5μg
5 Comparison of Different Methodologies Assessing Airway Responsiveness and Investigation of Treatment Efficacy of Budesonide /Formoterol in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
6 Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
7 Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Unknown status NCT02787863 Phase 4 Polioxidonium
8 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
9 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
10 Blood and Urinary Concentrations of Inhaled Salmeterol in Asthmatic Subjects and Elite Athletes With Asthma. Unknown status NCT00914901 Phase 4 inhaled salmeterol
11 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
12 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
13 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
14 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
15 A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma. Unknown status NCT01939951 Phase 4
16 A Multicentered, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Procaterol Hydrochloride With Inhaled Glucocorticoid in Treatment Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
17 Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma Unknown status NCT00914654 Phase 4 inhaled formoterol
18 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
19 Efficacy of Bronchial Thermoplasty in Korean Patients With Severe Asthma Unknown status NCT02031263 Phase 4
20 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
21 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia-single Center,Randomized,Double-blind，Controlled Trial Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
22 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Unknown status NCT03034005 Phase 4 Budesonide
23 Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02053402 Phase 4 Vitamin D
24 Asthma and Vitamin D (a Clinical Pilot Study) Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
25 Efficacy and Safety of Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children: A Double-Blind, Randomized, and Placebo-Controlled Study Unknown status NCT00172341 Phase 4 Staloral TM
26 Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration. Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
27 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
28 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
29 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery: a 9-month Randomized, Open-label, Controlled Study Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
30 Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS. Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
31 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
32 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
33 Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial Unknown status NCT02584738 Phase 4 Nebulized Magnesium Sulfate;Nebulized isotonic saline;Nebulized Salbutamol;Ipratropium bromide;Methylprednisolone or Prednisolone
34 Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment. Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
35 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma Unknown status NCT00385359 Phase 4 Albuterol
36 Does a Low Exhaled Nitric Oxide Level Exclude a Clinical Benefit From Inhaled Corticosteroids in Suspected Asthma: A Randomised, Placebo Controlled Trial Unknown status NCT02771717 Phase 4 Budesonide (Pulmicort);Placebo - dummy inhaler
37 Randomised, Double-blinded, Placebo-Controlled Study of Therapeutic Effect of Su-Huang Antitussive Capsule on Cough Variant Asthma(CVA) Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
38 Extra-fine Formoterol/Beclomethasone in the Treatment of Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
39 Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Leukotriene Modulator Montelukast Alone or Combined With Inhaled Corticosteroid on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
40 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
41 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
42 Randomized Double-blind Placebo-controlled Crossover Study to Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function in COPD Patients. Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
43 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
44 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
45 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
46 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
47 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
48 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
49 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
50 A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients Unknown status NCT01431859 Phase 4

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Albuterol
ALBUTEROL SO4 PWDR
Albuterol Sulfate
Aminophylline
aminophylline dihydrate
AMINOPHYLLINE PWDR
ANTIASTHMA,ANTILEUKOTRIENES
ANTIASTHMA,OTHER
ANTIASTHMA/BRONCHODILATORS
ANTI-INFLAMMATORIES,INHALATION
bitolterol
bitolterol mesylate
BRONCHODILATORS,ANTICHOLINERGIC
BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION
BRONCHODILATORS,SYMPATHOMIMETIC,ORAL
BRONCHODILATORS,XANTHINE-DERIVATIVE
Cromolyn
Cromolyn Sodium
Ephedra vulgaris preparation
Ephedrine
Ephedrine hydrochloride
Ephedrine sulfate
EPHEDRINE TANNATE
formoterol
formoterol fumarate
formoterol fumarate dihydrate
iodinated glycerol
Isoetharine
Isoetharine hydrochloride
Isoetharine Mesylate
metaproterenol
Metaproterenol Sulfate
montelukast
montelukast sodium
oxtriphylline
pirbuterol
Pirbuterol acetate
Pseudoephedrine
Pseudoephedrine Hydrochloride
Pseudoephedrine sulfate
salmeterol
Salmeterol xinafoate
Terbutaline
Terbutaline Sulfate
Theophylline
Theophylline anhydrous
Theophylline calcium salicylate
Theophylline Sodium Glycinate
zafirlukast
zileuton

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 20801416 21653527

Cochrane evidence based reviews: asthma

Sources

Genetic Tests for Asthma

About this section

Genetic tests related to Asthma:

# Genetic test Affiliating Genes
1 Asthma, Susceptibility to 29 ADRB2 ALOX5 CCL11 HLA-G HNMT IL13 MUC7 PLA2G7 SCGB3A2 TNF
2 Asthma 29
Sources

Anatomical Context for Asthma

About this section

MalaCards organs/tissues related to Asthma:

40
Lung, Testes, T Cells, Heart, Smooth Muscle, Neutrophil, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Affected by disease, potential therapeutic candidate
Sources

Publications for Asthma

About this section

Articles related to Asthma:

(show top 50) (show all 32817)
# Title Authors PMID Year
1
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. 54 61 56 6
11709756 2002
2
A hexanucleotide repeat upstream of eotaxin gene promoter is associated with asthma, serum total IgE and plasma eotaxin levels. 54 56 6
17220216 2007
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 54 56 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 54 56 6
14681301 2004
5
A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma. 54 56 6
11813133 2002
6
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 54 56 6
11896460 2002
7
Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. 54 56 6
11588017 2001
8
Genetic polymorphism of MUC7: allele frequencies and association with asthma. 61 56 6
11378823 2001
9
Genetic variants of IL-13 signalling and human asthma and atopy. 54 56 6
10699178 2000
10
MUC7 haplotype analysis: results from a longitudinal birth cohort support protective effect of the MUC7*5 allele on respiratory function. 56 6
16759176 2006
11
Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. 54 61 56
12913068 2003
12
Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. 54 61 56
12110844 2002
13
Interleukin 9: a candidate gene for asthma. 54 61 56
9371819 1997
14
A large-scale, consortium-based genomewide association study of asthma. 61 56
20860503 2010
15
Variants of DENND1B associated with asthma in children. 61 56
20032318 2010
16
The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. 54 56
16841093 2006
17
Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. 54 6
16596417 2006
18
A testing framework for identifying susceptibility genes in the presence of epistasis. 54 56
16385446 2006
19
Protection from experimental asthma by an endogenous bronchodilator. 61 56
15919956 2005
20
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. 54 6
15867853 2005
21
NOD1 variation, immunoglobulin E and asthma. 61 56
15718249 2005
22
No association of histamine- N-methyltransferase polymorphism with asthma or bronchial hyperresponsiveness in two German pediatric populations. 54 6
15693910 2005
23
Lack of association of histamine-N-methyltransferase (HNMT) polymorphisms with asthma in the Indian population. 54 6
16205835 2005
24
Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. 54 56
15345705 2004
25
Association of Eotaxin gene family with asthma and serum total IgE. 54 56
12761043 2003
26
A major susceptibility gene for asthma maps to chromosome 14q24. 61 56
12119603 2002
27
Genetics of asthma and related phenotypes. 61 56
12065182 2002
28
STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. 54 56
11912176 2002
29
A genomewide search for quantitative-trait loci underlying asthma. 61 56
11673820 2001
30
TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. 54 56
11295643 2001
31
Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. 54 56
11093275 2000
32
Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. 54 56
10973279 2000
33
The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. 54 56
10733466 2000
34
Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. 54 6
10803682 2000
35
Prostaglandin D2 as a mediator of allergic asthma. 61 56
10720327 2000
36
Functional screening of an asthma QTL in YAC transgenic mice. 61 56
10508526 1999
37
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 54 6
10369259 1999
38
A genome-wide search for linkage to asthma. German Asthma Genetics Group. 61 56
10333435 1999
39
Asthma and bronchial hyperresponsiveness linked to the XY long arm pseudoautosomal region. 54 56
9782093 1998
40
A polymorphism of the CC16 gene is associated with an increased risk of asthma. 54 6
9643286 1998
41
Association between asthma and an intragenic variant of CC16 on chromosome 11q13. 54 6
9550363 1998
42
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. 54 6
9399966 1997
43
Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. 54 56
9372650 1997
44
Bronchial asthma: lessons from murine models. 61 56
9122154 1997
45
Asthma genetics: waiting to exhale. 61 56
9054928 1997
46
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 54 6
9062372 1997
47
Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. 54 6
7706471 1995
48
Asthma in Adults. 61 42
31757240 2020
49
PRKCA: a positional candidate gene for body mass index and asthma. 56
19576566 2009
50
An african-specific functional polymorphism in KCNMB1 shows sex-specific association with asthma severity. 56
18535015 2008